|
Cadence Meets With FDA, Will Resubmit Ofirmev NDA Within 30 Days
Cadence Pharmaceuticals plans to resubmit an NDA within 30 days for its pain treatment Ofirmev, the company’s only investigational product candidate,
based on an April 16 meeting with the FDA.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
|
Subscribe
Archives